Ligand Reports Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Ligand Pharma (LGND) Tops Q3 EPS by 54c
November 9, 2021 4:41 PM ESTLigand Pharma (NASDAQ: LGND) reported Q3 EPS of $1.58, $0.54 better than the analyst estimate of $1.04. Revenue for the quarter came in at $64.8 million versus the consensus estimate of $55.65 million.
GUIDANCE:
Ligand Pharma sees FY2021 EPS of $5.80-$6.05, versus the consensus of... More
